Previous close | 47.20 |
Open | 47.20 |
Bid | 39.80 |
Ask | 41.70 |
Strike | 190.00 |
Expiry date | 2025-01-17 |
Day's range | 47.20 - 47.20 |
Contract range | N/A |
Volume | |
Open interest | 152 |
Alnylam Pharmaceuticals Inc (ALNY) reports robust revenue growth and promising clinical developments in the first quarter of 2024.
Unraveling the Financial and Strategic Position of ALNY in the Biopharmaceutical Arena
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.